Skip to content

Randomized, trial evaluating efficacy of add-on imipramine in the control of Dental Pain

Randomized, double blind, clinical trial evaluating efficacy of add-on imipramine in the control of Dental Pain

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/12/002203
Enrollment
66
Registered
2011-12-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Indication for forceps extraction of one or more teeth and expected to experience pain.

Interventions

Intervention1: Imipramine with ibuprofen: imipramine (25 mg p.o.) will be given 30 minutes before extraction procedure follwed by 400 mg of ibuprofen Control Intervention1: Matching Placebo and ibupro

Sponsors

Postgraduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 18 to 30 years. Either sex. Indication for forceps extraction of one or more teeth and expected to experience pain. Willing to give informed consent

Exclusion criteria

Exclusion criteria: Grade 3 mobile tooth. Any local or systemic conditions contraindicating tooth extraction Pregnancy or breast-feeding Alcohol or substance abuse Any serious medical or psychiatric disorder History of stomach ulcers, stomach bleed, or other bleeding disorders Use of a prescription or over-the-counter (OTC) drug with which administration of ibuprofen or any other NSAID; paracetamol; or codeine or any other opioid is contraindicated (including: antipsychotics, antianxiety agents, or other central nervous system depressants [including alcohol]) Patient has hypersensitivity, allergy, or clinically significant intolerance to any medications to be used in the study, or related drugs

Design outcomes

Primary

MeasureTime frame
SPRID 0-6 (sum of pain intensity difference scores and pain relief scores from 0 to 6 hours after dosing)Timepoint: SPRID 0-6 (sum of pain intensity difference scores and pain relief scores from 0 to 6 hours after dosing)

Secondary

MeasureTime frame
SPRID2, and SPRID3 post-dosing, TOTPAR2, TOTPAR3, and TOTPAR6.Timepoint: 0, 2 and 6 hour;The cumulative proportion of subjects achieving "meaningful" and "first perceptible" relief (confirmed by "meaningful" relief) by each post-dosing time-point.Timepoint: 0, 2 and 6 hour

Countries

India

Contacts

Public ContactDr Debasish Hota
debhota@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026